Corbeil-Essonnes (near Paris), France, June 29, 2021 – Yposkesi, a leading contract development and manufacturing organization (CDMO) for companies developing cell and gene therapies, today announces the selection of its ‘Boost’ bioproduction project as part of the ‘Boost’ initiative. Plan de Relance ”from the French government, a program aimed at making the national bioproduction industry strategically more robust and economically resilient.
The main objective of the Boost project is to develop an exceptionally efficient viral vector production line from thawing of cells to aseptic filling of the final product.
Yposkesi is investing 5 million euros ($ 6 million) in the project which will result in a new generation 1000 liter platform with optimized manufacturing and control processes.
“Yposkesi is proud that our Boost project has been selected for funding under the French government’s ‘Plan de Relance’ program,” said Alain Lamproye, Executive Chairman of Yposkesi. “The establishment of a large-scale GMP production line will allow us to achieve significant economies of scale and reduce production costs, while shortening the production time of equal amounts of active substances. Our goal is to help underserved patient populations access advanced therapies. “
Gene therapies are highly demanded transformational treatments for rare diseases. However, their biological and structural complexities make them one of the most difficult and expensive therapies to manufacture. As drug developers increasingly advance gene therapy treatments from clinical batches to commercial batches, larger scale viral vector capacity is required. Yposkesi is stepping up its investment in resources to address this bottleneck.
Currently, Yposkesi is producing batches of viral vectors (bioengineering tools that transport modified genetic material into tissues) at the scale of two 200-liter bioreactors. Thanks to the Boost project, one of its four production suites will be able to produce batches at the scale of a 1000-liter bioreactor, for the upstream (cell culture) and downstream (purification) parts of the process.
The Boost project will also improve the filling capacity of active ingredient bottles in the primary packaging of 2000/3000 bottles per campaign, resulting in a 10-fold increase in filling rate capacities.
“The deployment of new infrastructures and their optimal use cannot be done without technological innovation,” added Mr. Lamproye. “Part of this project will focus on the construction in silico tools for analyzing and modeling the data generated to optimize, as well as better control and make predictions about our processes.
Note to editor:
France’s recovery plan for strategic industries
France’s economic recovery plan, the Plan de Relance, is administered by the country’s Ministry of the Economy and Finance. It includes financing instruments to support specific industries deemed strategic for the nation’s economic recovery and industrial sovereignty; bioproduction is one of those industries. This massive recovery plan aims to make the French industrial economy more competitive by modernizing the production tool and securing the supply chain.
Yposkesi is a leading contract development and manufacturing (CDMO) organization for companies developing cell and gene therapies. Yposkesi offers high-quality, end-to-end viral vector CDMO services from clinical phase I / II to commercial manufacturing. Since March 2021, Yposkesi has welcomed SK Pharmteco, a global player in CDMO, as its main shareholder. Yposkesi’s current 50,000 feet2 (approximately 5,000 m2) operates several manufacturing suites for bulk drug substance (up to 1000 L) and filling and finishing. By 2023, Yposkesi will increase its global footprint to 100,000 feet2 (approximately 10,000 m2) with a second full-scale facility designed for EMA and FDA compliance. Yposkesi employs 185 people and is located on the Genopole Innovation Campus in Corbeil-Essonnes (south of Paris), France.